The putative JAK-STAT inhibitor AG490 exacerbates LPS-fever, reduces sickness behavior, and alters the expression of pro- and anti-inflammatory genes in the rat brain

Neuropharmacology. 2013 Aug:71:98-111. doi: 10.1016/j.neuropharm.2013.03.014. Epub 2013 Mar 30.

Abstract

The functional significance for activation of inflammatory transcription factors, such as signal transducer and activator of transcription (STAT3), nuclear factor (NF)κB or NF-interleukin (IL)6 and their contribution to the induction of brain controlled sickness responses, such as fever, during infection and inflammation is unknown. Using AG490, previously shown to inhibit the STAT3- and NF-IL6-signaling pathway, we therefore investigated the central involvement of these two signaling pathways in mediating sickness behavior, fever and accompanying brain inflammation induced by peripheral lipopolysaccharide (LPS)-stimulation. Rats pre-treated i.c.v. with AG490 1 h before the i.p. LPS-challenge (100 μg/kg) showed a modestly exaggerated fever, attenuated adipsia and almost unimpaired locomotor activity compared to LPS-controls receiving vehicle (i.c.v.). The LPS-induced anorexia was not altered and AG490 did not have any effect on rats receiving PBS (i.p.). We did observe effects of AG490 on STAT3-signaling at 4 h, while AG490-mediated changes in brain activity of inflammatory transcription factors at 8 h were not significant. Increased NF-IL6 and suppressor of cytokines 3 mRNA-expression in AG490/LPS-treated rats were indicative of a compensative activation at 24 h. Moreover, a significant decrease in hypothalamic anti-inflammatory IL-10-expression and an increase in inflammatory microsomal prostaglandin E synthase (mPGES) mRNA-expression 8 h after LPS-injection was revealed in AG490 pre-treated animals compared to solvent-treated LPS-controls. In summary, we have shown a dissociation between the effects of central AG490 treatment on fever and components of sickness behavior, which appears to be related to reduced IL-10 and increased mPGES-expression in the brain. Thus, AG490 might have therapeutic potential to reduce sickness behavior.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Behavior, Animal / drug effects
  • Body Temperature Regulation / drug effects
  • Brain / drug effects*
  • Brain / immunology
  • Brain / metabolism
  • Brain / pathology
  • Disease Models, Animal
  • Encephalitis / immunology
  • Encephalitis / metabolism
  • Encephalitis / pathology
  • Encephalitis / prevention & control*
  • Enzyme Inhibitors / administration & dosage
  • Enzyme Inhibitors / adverse effects
  • Enzyme Inhibitors / therapeutic use*
  • Gene Expression Regulation / drug effects*
  • Inflammation Mediators / agonists
  • Inflammation Mediators / antagonists & inhibitors
  • Inflammation Mediators / metabolism
  • Injections, Intraventricular
  • Janus Kinases / antagonists & inhibitors*
  • Janus Kinases / metabolism
  • Lipopolysaccharides
  • Male
  • Nerve Tissue Proteins / antagonists & inhibitors
  • Nerve Tissue Proteins / genetics
  • Nerve Tissue Proteins / metabolism
  • Neurons / drug effects
  • Neurons / immunology
  • Neurons / metabolism
  • Neurons / pathology
  • RNA, Messenger / metabolism
  • Rats
  • Rats, Wistar
  • STAT Transcription Factors / antagonists & inhibitors*
  • STAT Transcription Factors / metabolism
  • Tyrphostins / administration & dosage
  • Tyrphostins / adverse effects
  • Tyrphostins / therapeutic use*

Substances

  • Enzyme Inhibitors
  • Inflammation Mediators
  • Lipopolysaccharides
  • Nerve Tissue Proteins
  • RNA, Messenger
  • STAT Transcription Factors
  • Tyrphostins
  • alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide
  • Janus Kinases